Back to top
more

MacroGenics (MGNX)

(Delayed Data from NSDQ)

$16.23 USD

16.23
646,315

+1.22 (8.13%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $16.24 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MGNX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MacroGenics, Inc. [MGNX]

Reports for Purchase

Showing records 281 - 300 ( 360 total )

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 281

05/14/2015

Industry Report

Pages: 9

ASCO 2015 Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 282

05/07/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 283

05/07/2015

Company Report

Pages: 5

Rich Pipeline Continues to Advance; Early ''271 Data in H2:15, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 284

05/07/2015

Company Report

Pages: 8

1Q15 Takeaways; Robust Pipeline and Clinical Program Growth

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 285

05/01/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 286

04/24/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 287

04/20/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 288

04/19/2015

Company Report

Pages: 5

Advantage DART''s as Preliminary Solid Tumor CAR-T Underwhelms

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 289

04/07/2015

Industry Report

Pages: 2

Healthcare -Biotechnology: Catalyst Tracker Through Mid-15

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 290

03/30/2015

Industry Report

Pages: 2

Healthcare: Biotechnology: Its Yogi Berra All Over Again

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 291

03/20/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 292

03/19/2015

Company Report

Pages: 5

First Peek at Future DART Targets from the AACR-15

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 293

03/17/2015

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 294

03/16/2015

Daily Note

Pages: 5

Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 295

03/16/2015

Daily Note

Pages: 6

Another Day and Another DART Heads to the Clinic

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 296

03/16/2015

Daily Note

Pages: 5

MGNX''s Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 297

03/16/2015

Industry Report

Pages: 2

Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 298

03/04/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 299

03/03/2015

Company Report

Pages: 6

Q4:14 EPS; on Track for Multiple Trial Initiations for 2015; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: MacroGenics, Inc.

Industry: Medical - Products

Record: 300

03/03/2015

Company Report

Pages: 8

Well Positioned and Expanding Pipeline Supported by Cash till 2018

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party